WGS· Health Care› Diagnostics & Research

GeneDx Holdings Corp. Class A

Stage 2 · Advancing · week 4

As of Oct 22, 2026, GeneDx Holdings is in Stage 2, the uptrend phase, now in week 4 (since Sep 28, 2026). It closed at $67.14, 59.9% below its 52-week high and below its 200-day average, which is falling.

GeneDx Holdings Corp., a genomics company, provides genetic testing services. More about the company

$67.14

-2.61% today

$2.0B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care

Is WGS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 22w

S2 49w

S2 24w

S4 20w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 22w → S1 7w → S2 49w → S3 1w → S2 12w → S3 7w → S4 3w → S1 2w → S2 24w → S3 5w → S4 20w → S1 10w → S2 4w current

Total tracked: 166 weeks across 13 stage runs.

WGS among Diagnostics & Research38th of 44 by relative strength

All 44 →

Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CDNACareDx, Inc.	Stage 2 · wk 24	99	+27.3%
2	BDSXBiodesix, Inc.	Stage 2 · wk 18	98	−18.3%
3	ILMNIllumina, Inc.	Stage 2 · wk 24	97	+5.5%
4	GHGuardant Health, Inc.	Stage 2 · wk 21	97	−7.6%
5	NTRANatera, Inc.	Stage 2 · wk 20	96	+2.7%
6	CRLCharles River Laboratories International, Inc.	Stage 2 · wk 16	92	+22.5%
7	RVTYRevvity, Inc.	Stage 2 · wk 18	90	+10.7%
8	PSNLPersonalis, Inc.	Stage 2 · wk 17	90	−3.2%
…38	WGSGeneDx Holdings Corp. Class A	Stage 2 · wk 4	26	−21.2%

vs 52W High

-59.9%

$34.51 lo$167.52 hi

59.9% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 4

1w13w26w

Week 4, early Stage 2

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-8.9%

200 DMA: $73.72 · sloping down

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.84x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-21.2%

+13.6%

+1.4%

YTD

-49.3%

-44.9%

Scan Membership

Breakout Watch

Latest: 2025-02-20

2 appearances in last 60 days. First seen: 2024-03-05.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 4 · Vol 0.84x

2026-10-21S2

Wk 4 · Vol 0.69x

2026-10-20S2

Wk 4 · Vol 1.10x

2026-10-19S2

Wk 4 · Vol 0.76x

2026-10-16S2

Wk 3 · Vol 0.96x

2026-10-15S2

Wk 3 · Vol 1.19x

2026-10-14S2

Wk 3 · Vol 1.36x

2026-10-13S2

Wk 3 · Vol 0.72x

2026-10-12S2

Wk 3 · Vol 0.67x

2026-10-09S2

Wk 2 · Vol 0.54x

2026-10-08S2

Wk 2 · Vol 0.98x

2026-10-07S2

Wk 2 · Vol 0.87x

Moving averages & range

50 DMA

$80.81

200 DMA

$73.72

52W High

$167.52

52W Low

$34.51

5D Low

$63.61

Resistance levels (recent highs)

20d High

$88.40

60d High

$104.95

120d High

$104.95

250d High

$167.52

Next resistance

+31.7%

to 20d High

ROE

-40.8%

Profit margin -23.4%

Dividend Yield

0.00%

P/B 8.2

GeneDx Holdings: quick answers

What stage is GeneDx Holdings in?

As of Oct 22, 2026, GeneDx Holdings (WGS) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 28, 2026 and is in week 4. What the four stages mean

Is GeneDx Holdings in an uptrend?

Yes. GeneDx Holdings is in a Stage 2 uptrend. It trades 8.9% below its 200-day average, which is falling.

How far is GeneDx Holdings from its 52-week high?

GeneDx Holdings closed at $67.14 on Oct 22, 2026, 59.9% below its 52-week high of $167.52. Its 52-week low is $34.51.

How has GeneDx Holdings performed over the past year?

As of Oct 22, 2026, GeneDx Holdings is down 44.9% over the past year and down 49.3% so far in 2026.

Which sector and industry is GeneDx Holdings in?

GeneDx Holdings is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.